Current Data Requests

The Maine Health Data Organization has, in accordance with Rule Chapter 120: Release of Data to the Public, instituted a process for the purpose of notifying users and providers of health care data when the MHDO receives a request for health data and accepts that request. In addition to sending electronic notification to interested parties and to providers that are responsible for the submission of the data, we provide the summary page of the ten most recent data requests below. If you are interested in seeing requests prior to the last on this page, you will find them here: https://mhdo.maine.gov/dataRequests_Archived.htm

For all data requests, the data providers or other interested parties may submit comments related to the data request to the Executive Director. To be considered, comments must be received by the Executive Director in writing or by electronic notification no later than thirty business days after the initial posting of the data request on the MHDO web site. If the Executive Director determines that (a.) the comments received are of significant enough importance to delay the release of data and/or (b.) additional information is required from the requesting party to address the comments; then the data shall not be released until the additional information has been received from the requesting party and an additional review is conducted by the Executive Director or the MHDO Data Release Subcommittee, as applicable, to ensure that the requesting party conforms to all applicable requirements of this chapter.

The Executive Director will bring all comments received from the data providers and or other interested parties for the release of Level III Data to the MHDO Data Release Subcommittee for consideration.

Individuals who want to opt out of a specific Level III data request may do so by completing this MHDO Choice Disclosure Form no later than 30 business days after the initial posting of the data request. If you opt out of Level III data requests, you will remain opted out unless you choose to opt back in via completion of the MHDO Choice Disclosure Form.

NOTE: If you would like to be notified when new data requests are posted, please email your request.

Request #	Organization and Data Applicant	Consultant	Comment Close Date	Data Requested	Purpose of Request, Benefits to the Citizens of Maine, and Public Reporting Plans	Request Status (Approved or Withdrawn)
2025071401	ME CDC, The Maine Immunization Program Kristina Mead	N/A	11/21/2025	MHDO Ad Hoc Request – Q1 2022 through Q4 2024 Adult Vaccinations by Age, County, Anonymized Payer Type, Billing Provider, Service Location and Vaccine Type.	The Maine Immunization Program is requesting MHDO to produce aggregate data on adult vaccinations to help support the financial assessment for LD 93. LD 93 seeks to expand the Universal Childhood Immunization Program to provide immunizations to and cover the costs of recommended vaccines for adults in the State of Maine. This expansion ensures that all Mainers, regardless of age, can access vaccines to protect against preventable diseases while promoting health equity. By broadening access to vaccinations for adults, this initiative will provide preventative care for adults 19-64 years old and increase access points around the State for adult patients. This project benefits the citizens of Maine by reducing barriers adults in Maine face accessing vaccines, including high insurance deductibles, limited access points, and limited vaccines, which leaves this population vulnerable to preventable disease. By broadening this program to include Maine adults we eliminate these barriers, along with vaccine preventable diseases, ensuring that all recommended vaccines are readily available to every adult in Maine.
2025012203	Abound Health Jacob Johnson	N/A	11/21/2025	MHDO Ad Hoc Request – Level I CY 2023 Claims Data for Home and Community Services	Abound Health is focused on expanding access to high-quality services for individuals with intellectual and developmental disabilities (IDD) by offering comprehensive, person-centered services. They provide a full array of Innovations Waiver Services, Medicaid B3 Services, Medicaid State Funded Services, plus Private Pay and Insurance Options. They are requesting aggregated claims data from the Maine Health Data Organization (MHDO) for Calendar Year 2023. The request focuses on services provided under Home and Community Services for adults with intellectual disabilities and autism spectrum disorder. Specifically, they are requesting claims by providers for the following CPT Codes: H2014, H2015, H2016, T2020, H2021, T2021, H2023, H2025, T2019, T2024, and H2026. The purpose of this request will help them to assess gaps in care, identify areas of need, and better understand how providers are serving individuals across the state of Maine. Their goal is to support efforts that improve service availability, continuity of care, and overall outcomes for Maine residents with IDD.
2025080402	State of Maine Office of Affordable Health Care Katherine Senechal	Wakely an HMA company	11/05/2025	MHDO Level II Q3 2025 – Q2 2026 Inpatient and Outpatient Hospital Encounter Data, Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility including City/ZIP, Race & Ethnicity, Practitioner Identifiers, Payer Name/ID, De-identified Person Directory and Hospital Healthcare Quality Data (CMS Measures)	This data request seeks to add additional quarters of MHDO data (Q3 2025 – Q2 2026) to previously approved data request number 2024082001. In addition, Wakely will be added as a data consultant to support data analysis to the previously requested CY 2024 Medical Claims and Eligibility data. In 2021, the Maine legislature created the Office of Affordable Health Care (OAHC) when it enacted P.L. 2021 Chapter 459, Section 3. Among other duties, the establishing legislation directs the office to analyze health care cost growth and spending trends, including correlation to quality and consumer experience, and to develop proposals to improve the affordability, quality, and efficiency of health care in Maine. This project builds upon the previously authorized MHDO data request 2024020502 and seeks to further analyze trends in payor and provider health care spending, health care consumption, and the costs of providing health care using MHDO data beginning in 2017 through the most current data available from MHDO. This request allows OAHC to directly access MHDO data via the NORC Data Enclave. The Office, mandated to identify drivers of health care costs and quality, requires Payer Name/ID information to understand differences in healthcare payments and coverage, allowing for analysis of policy impacts on specific payors and connecting observed trends to policy decisions, demographics, and other factors such as health insurance coverage for services. This project will advance the aims of the office by offering data driven insights into drivers of health care spending, obstacles to affordability, and care quality for Maine residents by creating summaries of aggregated data in proactive or responsive work products for the Maine legislature and other stakeholders. These products may include annual reports, legislative inquiries, and presentations for the public and the Advisory Council on Affordable Health Care.
2025041501	Sg2 Tanya Chin-Fatt	N/A	10/17/2025	Q2 2024 – Q2 2026 MHDO Level II Hospital Inpatient Encounter Data including City/ZIP	This data request seeks to add an additional year of MHDO data to previously approved data request number 2023072701. MHDO’s hospital discharge data will be used in Sg2's online analytics tools to explore historical trends and develop demand forecasts by clinical area and geography; allowing several Maine Hospitals and Hospital Systems working with Sg2 to project and meet future demands by determining the appropriate allocation of resources to improve both the quality and availability of health care in the communities they serve. Sg2 applies proprietary CARE groupings to quantify baseline volumes, then applies its Impact of Change model to project demand for health care services over the next decade, examining the cumulative effects and interdependencies of key impact factors driving change in utilization in major Maine markets. Using both disease-based and MS-DRG–based analyses, the forecast provides a comprehensive picture of how patients will access services along the continuum of care. The resulting output can be visualized at the service area, zip code, service line, disease, and procedure levels which health systems serving Maine residents use to develop their operational and strategic plans.
2025042902	University of Kentucky Chris Delcher	N/A	8/26/2025	MHDO Level II Q1 2022 – Q4 2023 Custom Extract: Includes Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility, Practitioner Identifiable Data, City/Zip and Race and Ethnicity.	The aim of this study is to compare the on-label prescribing of psychotropic medications for individuals with autism spectrum disorder (ASD) to the general population (referred to as “non-ASD controls”). Individuals with ASD often experience co-occurring conditions at higher rates than the general population, including attention deficit hyperactivity disorder (ADHD), depressive disorders, anxiety, bipolar disorder, and epilepsy; and it is known that patients with ASD are vulnerable to overprescribing to treat challenging behaviors. By examining medication utilization patterns in the MSDI data, we can investigate differences in treatment approaches and identify areas for improvement in the management of ASD and its co-occurring conditions for Maine residents. Patients with ASD will be identified based on specific diagnostic criteria, including inpatient and outpatient claims with an ASD diagnosis and continuous enrollment in medical and pharmacy benefits. Propensity score matching will be used to create a 1:5 control population without ASD, ensuring demographic similarity between groups. On-label prescribing for various medication types, including ADHD medications, antidepressants, anxiolytics, antiepileptics, and mood stabilizers/antipsychotics will be the primary outcome. On-label prescribing will be defined as patients with a diagnosis followed by a respective prescription fill within 7 days. Difference in number of medication types will be examined between the ASD and control group using negative binomial regression. Our project is guided by a team of research and clinical experts convened from the state. On-going meetings will help ensure that analyses and research questions are relevant to improving health outcomes in Maine. By fostering a deeper understanding of these prescribing patterns, healthcare providers in Maine can better tailor treatment strategies to meet the diverse needs of individuals with ASD, ultimately improving their overall quality of life.
2025032502	University of Utah Kim Jaewhan	N/A	8/26/2025	MHDO Level II Q1 2022 – Q4 2023 Custom Extract: Includes Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility, Practitioner Identifiable Data, City/Zip and Race and Ethnicity.	This project aims to provide valuable insights into the effectiveness of bariatric surgery versus weight loss medications among Maine residents. The Maine Health Data Organization (MHDO) data will play a crucial role in achieving the project's objectives by providing comprehensive information on patient demographics, clinical characteristics and allowing for a detailed comparison between individuals who undergo bariatric surgery and those who receive weight loss medications. The project will examine four key areas: 1.) Differences in characteristics of subjects undergoing bariatric surgery versus weight loss medication treatment. 2.) Differences in the incidence of mental disorders following bariatric surgery compared to weight loss medication prescriptions. 3.) Comparison of all-cause and diabetes-related ER visits and hospital admissions following bariatric surgery versus weight loss medication prescriptions. 4.) Comparison of total healthcare spending between subjects who underwent bariatric surgery and those who received weight loss medication prescriptions. This research will benefit the citizens of Maine by providing insight into healthcare utilization, cost comparisons, and economic impacts of bariatric surgery and weight loss medications. Findings will help Maine policymakers and healthcare organizations develop cost-effective obesity management strategies. We plan to publish 4 papers using MHDO data in open access journals. As part of our dissemination plan, we will share all key findings and reports with the Maine Quality Forum (MQF), a state agency that plays a vital role in informing public health policy in Maine. This will facilitate timely dissemination and use of our research to support data-driven policy decisions aimed at improving healthcare delivery and population health in Maine. By bridging clinical evidence with policy application, this work will enhance healthcare practices, optimize resource use, and promote healthier communities throughout Maine.
2025051901	Northern Light Health Jose Alicea-Santiago	N/A	7/30/2025	MHDO Level II Q1 2025 – Q4 2025 Hospital Inpatient and Outpatient Encounter Data, including City/ZIP, Race & Ethnicity, Practitioner Identifiable data and Integrated Cancer-Incidence Registry Data.	This data request seeks to add an additional year of MHDO data to previously approved data request number 2024041901. Northern Light Health (NLH) will continue to use the MHDO’s inpatient and outpatient hospital data to support its member organizations and their planning efforts to advance initiatives that are important to the hospital system, the people of Maine, and the State’s healthcare system. To improve the health of the people and communities served, NLH will continue to analyze patient origin and demographics, locations of healthcare services and providers, healthcare services utilization rates and volumes and healthcare services provided, including diagnoses and procedures. The benefits to the citizens of Maine include optimized resource allocations, better planning by understanding care delivery factors like distances traveled by patients, and refined program planning for specific age groups. Race and ethnicity data addresses gaps around health care equity. The MHDO’s integrated Cancer-Incidence Registry data informs developments in Oncology services that are especially important given reported increases in overall cancer incidence and among younger age groups. Provider identification data supports decision-making for future placement of services and/or collaborative efforts.
2025032802	Depts. of Population Health Sciences and Medicine Duke University School of Medicine Virginia Wang	N/A	7/30/2025	MHDO Level II Q1 2022 – Q4 2023 Custom Extract: Includes Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility, Practitioner Identifiable Data, MHDO De-Identified Person Directory, and City/Zip, Race and Ethnicity.	This research project will be divided into two parts: 1. Assessing Primary Care Involvement and Care Fragmentation among Dialysis Patients: This analysis will examine the role of primary care and the extent of care fragmentation among dialysis patients. By analyzing differences in primary care use and the degree of care coordination across providers, the study will assess clinical characteristics, utilization patterns, and the quality of care received by dialysis patients. The data will be aggregated for analysis in calendar year 2022-2023. Outcomes will include metrics such as the number of unique providers and continuity of care indices. This project will benefit the citizens of Maine by providing valuable insights into healthcare utilization and care fragmentation among dialysis patients. The findings may inform strategies to improve care coordination and access, reduce fragmentation, and enhance health outcomes, particularly for those with End-Stage Kidney Disease. The analysis will also support more efficient use of healthcare resources and improve access to consistent care for Maine residents. 2. Estimating the Unmet Need and Patterns of GLP-1 Utilization Among Medicaid Patients in Maine, Colorado and Virigina: This component aims to evaluate the use of GLP-1 receptor agonists (e.g., semaglutide and tirzepatide) and estimate the unmet need for these medications. A descriptive analysis will be conducted to characterize Medicaid patients who have used GLP-1 medications, focusing on their demographic and clinical profiles, to better understand access and utilization. The study will explore potential gaps in treatment as well as the prevalence of conditions such as obesity and diabetes. This component will benefit the citizens of Maine by exploring potential gaps in treatment, as well as support state policymakers and health administrators in developing strategies to expand access to GLP-1 therapies and improve treatment for patients with obesity and diabetes. The findings can support data-driven decisions on Medicaid coverage policies and resource allocation.
2025032201	Center for Improving Value in Health Care (CIVHC) Darcy Holladay Ford	N/A	7/23/2025	MHDO Level II Q1 2022 – Q4 2023 Custom Extract: Includes Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility, Practitioner Identifiable Data, MHDO De-Identified Person Directory, and City/Zip, Race and Ethnicity.	This research project is conducting a Medicare Advantage (MA) analysis in partnership with the Commonwealth Foundation. Our Medicare Advantage analysis aims to understand Medicare Advantage plan enrollment by year, the associated medical costs, and differences in utilization by plan type (PPO, HMO, EPO). Rural versus metropolitan areas are particularly interesting, allowing the research team to compare Maine, which has a primarily rural designation, with Virginia and Colorado, which balance urban and rural areas in the CO frontier. The benefits to the citizens of Maine are to understand the footprint of MA plans in their aging populations and what impact this enrollment has on meeting the needs of their aging populations. Additionally, this analysis will be published nationally on the Commonwealth's website, allowing for a national understanding of Maine's MA footprint compared to Virginia's and Colorado's. This will allow for a greater understanding of regional drivers of Medicare Advantage enrollment, increase transparency, and allow for benchmarking across states. The analysis also examines the proportion of dually eligible members enrolled in Medicare Advantage (MA) and ancillary services and screenings coverage. This study aims to understand the cost and utilization impact of a growing Medicare Advantage (MA) population across states.
2025032002	Center for Improving Value in Health Care (CIVHC) Darcy Holladay Ford	N/A	7/23/2025	MHDO Level II Q1 2022 – Q4 2023 Custom Extract: Includes Medical Claims, Medical Eligibility, Pharmacy Claims, Pharmacy Eligibility, Practitioner Identifiable Data, MHDO De-Identified Person Directory, and City/Zip, Race and Ethnicity.	The Center for Improving Value in Health Care (CIVHC) Research & Evaluation team will conduct a cross-sectional analysis of maternal care trends through a health equity lens, focusing on the material prevalence of Pervasive Developmental Disorder and Autism Spectrum Disorder compared to controls across states, and examining procedures and diagnoses by member demographics. Rural versus metropolitan areas are of particular interest, allowing the research team to compare Maine, which has a primarily rural designation, with Virginia and Colorado, which have a balance of urban and rural areas in the CO frontier. The benefits to the citizens of Maine is to understand the maternal outcomes of a high-risk population to potentially allow for future intervention to lower an ever-growing maternal mortality and morbidity rate. Specifically, we are interested in understanding key maternal care measures among different groups, including those by age, race and ethnicity, geography, and among individuals with comorbidities or chronic conditions. This project aligns with our maternal health research agenda, and allow for a comprehensive comparative analysis of key therapeutic interventions, including treatments for anxiety and depression, as well as occupational therapy and physical therapy, to improve outcomes. Maternal care measures will be calculated using the CPT/ICD Procedure and Provider Taxonomy codes. They may include prenatal care, vaginal versus cesarean delivery, complication rates, types of delivery providers, and lactation support.